A statement released earlier today by Zacks Investment Research about Hercules Capital Inc (NYSE:HTGC) bumps the target price to $15.00
- Updated: November 29, 2016
Zacks Investment Research bumped up the target of Hercules Capital Inc (NYSE:HTGC) to $15.00 stating a potential upside of 0.09%.
Boasting a price of $13.79, Hercules Capital Inc (NYSE:HTGC) traded 0.07% higher on the day. With the last close up 5.10% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Hercules Capital Inc has recorded a 50-day average of $13.53 and a two hundred day average of $13.10. Volume of trade was down over the average, with 270,800 shares of HTGC changing hands under the typical 298,456
With a total market value of $0, Hercules Capital Inc has price-earnings ratio of 14.81 with a one year low of $9.92 and a one year high of $14.00 .
A total of 10 analysts have released a research note on HTGC. Three analysts rating the company a strong buy, six analysts rating the company a buy, four analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $13.45.
More About Hercules Capital Inc (NYSE:HTGC)
Hercules Capital, Inc., formerly Hercules Technology Growth Capital, Inc., is a specialty finance company. The Company is focused on providing senior secured venture growth loans to venture capital-backed companies in a range of technology, life sciences and sustainable and renewable technology industries. The Company is an internally managed, non-diversified, closed-end investment company. The Company focuses its investments in companies active in the technology industry sub-sectors characterized by products or services, including computer software and hardware; networking systems; semiconductors; semiconductor capital equipment; information technology infrastructure or services; Internet consumer and business services; telecommunications; telecommunications equipment, and media. Within the life science sub-sector, the Company focuses on medical devices, bio-pharmaceutical, drug discovery, drug delivery, healthcare services and information systems companies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.